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Management of bipolar disorder 
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study in real-life conditions
Ludovic Samalin1,2, Eduard Vieta2, Tarek Ahmed Okasha3, MM. Jalal Uddin4, Seyed Ali Ahmadi 
Abhari5, Fethi Nacef6, Vyacheslav Mishyiev7, Dovi Aizenberg8, Yaël Ratner9, Lydie Melas-Melt10, 
Idir Sedeki11 & Pierre Michel Llorca1
Most of the existing data on real-life management of bipolar disorder are from studies conducted in 
western countries (mostly United States and Europe). This multinational, observational cohort study 
aimed to describe the management and clinical outcomes of bipolar patients in real-life conditions 
across various intercontinental countries (Bangladesh, Egypt, Iran, Israel, Tunisia, and Ukraine). Data 
on socio-demographic and disease characteristics, current symptomatology, and pharmacological 
treatment were collected. Comparisons between groups were performed using standard statistical 
tests. Overall, 1180 patients were included. The median time from initial diagnosis was 80 months. 
Major depressive disorder was the most common initial diagnosis. Mood stabilizers and antipsychotics 
were the most common drugs being prescribed at the time of the study. Antidepressants (mainly 
selective serotonin uptake inhibitors [SSRIs]) were administered to 36.1% of patients. Patients 
with bipolar I disorder received higher number of antipsychotics and anxiolytics than those with 
bipolar II disorder (p < 0.001). Presence of depressive symptoms was associated with an increase in 
antidepressant use (p < 0.001). Bipolar disorder real-life management practice, irrespective of region, 
shows a delay in diagnosis and an overuse of antidepressants. Clinical decision-making appears to be 
based on a multidimensional approach related to current symptomatology and type of bipolar disorder.
Bipolar disorder (BD) is a recurrent and chronic disease characterized by the occurrence of manic (or hypo-
manic), depressive, or mixed episodes. According to the World Health Organization, BD is one of the world’s ten 
most disabling conditions1. Several studies have shown that a considerable proportion of BD patients (30–60%) in 
clinical remission live with significant functional impairment2–6. In the general population, the estimated lifetime 
prevalence of BD is approximately 0.2–5% and increases to 6% for a broad range of bipolar spectrum disorders7–10. 
A first depressive episode, the presence of psychotic symptoms, and/or various comorbidities can dissimulate 
bipolar symptoms and may result in a delay in the diagnosis of BD. An estimated 35–45% of BD patients are 
misdiagnosed with unipolar depression11–14, and delays of up to 20 years from the onset of symptoms to the first 
mood stabiliser treatment have been reported11. Although the disease burden appears equivalent in both BD 
types12, the longitudinal course of patients with bipolar II disorder (age of onset, clinical course, predominant 
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polarity, duration of episodes, and suicidality) differs from patients with bipolar I disorder13. Consequently, the 
risks of delayed diagnosis and misdiagnosis (as unipolar depressive disorder, personality disorders, or mild bipo-
lar I disorder) are likely to be higher in bipolar II patients than in bipolar I patients.
Management of BD (type I or II) comprises complex treatment regimens to achieve the stabilisation of a mood 
episode and then the prevention of relapses or recurrences to allow for functional recovery. In recent decades, 
an increasing number of drugs, including lithium, anticonvulsants, and more recently second-generation antip-
sychotics, have been approved for the treatment of BD, presenting a new challenge for clinicians in choosing the 
most appropriate medication. Numerous guidelines have been developed by national agencies and professional 
organisations to guide clinicians to make their choice in the practice of appropriate evidence-based care14–18. 
However, many clinicians do not adhere to guidelines in routine practice, potentially due to negative attitudes 
toward guidelines (guidelines “are published by experts and not clinicians,” “are biased,” and “do not correspond 
to my patients” were some of the more telling responses from clinicians recently surveyed about their percep-
tions of the methods used in the evidence based-guidelines)19,20. Indeed, guidelines are often limited by the fact 
that they are typically based on the positive results of randomised controlled double-blind trials, which include 
BD patients only under restrictive criteria (e.g., monotherapy, exclusion of patients with medical or psychiat-
ric comorbidities) and for a limited duration of assessment. Considering the gap between the highly selected, 
controlled evidence from research studies and the management of BD patients in real-life conditions, the appli-
cability of guidelines in routine practice can be difficult to ascertain. Furthermore, the clinical management of 
BD patients can be affected by local customs, expert opinions, relationships with pharmaceutical industry, or 
politico-economic environments.
Most of the existing data on management of BD in real-life conditions are from studies conducted in western 
countries (particularly the United States and Europe)21–33. Few published trials have evaluated patients from other 
countries, and the data from these trials are very limited34. Therefore, the primary aim of the MAnagement of 
biPolar disorder in INtercontinental reGion (MAPING) study was to provide information on the management 
of BD patients in conditions representative of routine clinical practice across different countries (Bangladesh, 
Egypt, Iran, Israel, Tunisia, and Ukraine) from the intercontinental region. Secondary objectives were to compare 
clinical outcomes and management of patients according to BD type and current bipolar symptoms.
Methods
MAPING was an international, multicentre, non-interventional, cross-sectional study in adult BD patients con-
ducted between September 2013 and May 2014. The study was performed in accordance with the Declaration 
of Helsinki and was carried out with the approved guidelines. All experiments were approved by Institutional 
Review Board or Institutional Ethics Committee from each participating country (Tehran university of medical 
science, Tehran, Iran; Razi hospital, La Manouba, Tunisia; Hadassah Hospital, Jerusalem, Israel; Kyiv City Clinical 
Psycho-neurological Hospital, Kiev, Ukraine; Sher-e-Bangla Hospital, Dhaka, Bangladesh; Ain Shams Hospital, 
Cairo, Egypt). All patients provided written informed consent to participate in the study.
Selection of physicians. A feasibility study was conducted in potential study centres to confirm the capac-
ity of potential sites to recruit the targeted study population. In order to ensure representativeness of the sample, 
90 investigational sites (including psychiatric hospitals, general hospitals, and community office-based practices) 
were randomly selected from the pre-established list of study sites in Bangladesh, Egypt, Iran, Israel, Tunisia, 
and Ukraine. In the event that a physician declined to participate, s/he was replaced by the next physician on the 
randomised list.
Patient selection. The study included patients aged ≥ 18 years fulfilling Diagnostic and Statistical Manual 
of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) diagnostic criteria for BD type I, type II, or not 
otherwise specified, and gave the informed consent. Exclusion criteria were concurrent enrolment in another 
study and presence of any acute physical condition. All consecutive eligible patients, at each site, were included in 
the study for a period of 8 months.
Data collection. A site questionnaire collected the following information on the physicians: age, gender, 
specialty, years of practicing, main workplace (hospital, community, others), location, number of BD patients 
seen per month, knowledge and use of international and/or national guidelines (very frequently, from time to 
time, never).
Patients’ data were collected in a single visit by physician, who completed a case report form for each patient. 
Information collected included:
•	 Eligibility, date of visit and informed consent
•	 Patient characteristics: socio-demographic data (age, sex, area of residence, marital status, educational level, 
and medication health coverage), employment status, work disability, and physical comorbidities;
•	 Disease characteristics: type of BD, number of episodes and psychiatric hospitalizations during the last 12 
months, predominant polarity of episodes (manic or depressive predominant polarity), family history of 
psychiatric history, age at initial diagnosis, initial diagnosis type, age at BD diagnosis, socio-familial and 
occupational functioning during the last 2 months (assessed by the Global Assessment of Functioning [GAF] 
scale35);
•	 Current bipolar symptoms listed in the DSM-IV-TR diagnostic criteria for BD: manic symptoms (feeling 
unusually “high” and optimistic or extremely irritable, grandiose beliefs about one’s abilities or powers, sleep-
ing very little but feeling extremely energetic, talking so rapidly that others can’t keep up, racing thoughts, 
highly distractible or unable to concentrate, impaired judgment and impulsiveness, acting recklessly without 
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thinking about the consequences, delusions, and hallucinations) and depressive symptoms (feeling hopeless 
or sad or empty, changes in appetite or weight, sleep disturbances, concentration and memory problems, feel-
ing of worthlessness or guilt, thoughts of death or suicide, irritability, inability to experience pleasure, fatigue 
or loss of energy, and physical and mental sluggishness);
•	 Pharmacological treatment: treatment received at the time of initial diagnosis, antidepressant therapy at least 
once in life and if yes, the response to antidepressant (manic/hypomanic switches, resistance to treatment, 
mood lability, irritability, and unknown) and ongoing pharmacological treatment (mood stabilisers including 
lithium and anticonvulsants, first or second-generation antipsychotics, antidepressants, and electroconvulsive 
therapy).
Statistical methods. The primary endpoint was the description of BD management across various coun-
tries, which included pharmacological treatment received or ongoing, psychiatric hospitalizations during the last 
12 months and other healthcare resources use.
Secondary endpoints included the description of patients’ and diseases’ characteristics.
Comparisons were performed among:
•	 BD type I versus type II for the duration between initial identification of a pathological state and BD diagnosis 
(months), employment status, work disability, GAF score during the last 2 months, and ongoing pharmaco-
logical treatment (defined by class).
•	 Current bipolar symptoms and previous use of antidepressant (lifetime).
All analyses were conducted on the analysis population, by country and overall. The analysis population con-
sisted of all patients enrolled in the study who met all inclusion/exclusion criteria.
Descriptive statistics of continuous variables were presented as the number of data analyzed, mean, standard 
deviation, median, quartiles and extreme values. Descriptive statistics of categorical variables were presented as 
the number and proportion of patients in each category. Missing data were not counted in the percentage.
Statistical comparisons between groups were performed using Chi-square test or Fisher’s exact test for cate-
gorical variables. Quantitative variables were compared using the Student’s t-test when normality is verified or 
the Wilcoxon Mann-Whitney test otherwise. All analyses were two-tailed, and significance was set at p < 0.05.
All comparisons performed and all p-value calculated were provided only for descriptive purpose.
Bonferroni correction was applied for multiple testing (adjusted p = 0.0025).
Statistical analysis was performed using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Overall, 89 participating physicians in hospital- and office-based settings screened 1447 patients diagnosed with 
BD. Of these patients, 1180 (81.5%) were included in the trial as the eligible population for the statistical analysis. 
The main reason for non-inclusion was patient refusal. Table 1 summarizes the number of sites and participating 
physicians and the number of screened, included, and eligible patients.
Study sample characteristics. Physician characteristics. The mean age of participating physicians (77.5% 
men) was 50.6 ± 8.2 years with an average of 21.4 ± 8.3 years of practice. The median number of BD patients seen 
per month was 40. Most physicians (82.2%) used international guidelines very frequently (49.4%) or from time 
to time (48.3%).
Patient characteristics. Mean age was 37.9 ± 13.2 years, and 52.8% of patients were men (Table 2). Most patients 
were married and living in urban area. Overall, 79.8% of patients had a secondary or higher level of education, 
ranging from 61.3% in Bangladesh to 98.6% in Ukraine. For 52, 9% of patients, the medication health coverage 
was as out of pocket. Over half of the patients were unemployed, of whom, 47.0% of patients were unemployed 
because of a work disability.
Few patients (< 17%) had past or existing physical comorbidities: the most frequent comorbidities were obe-
sity, cardiovascular disease, diabetes, and thyroid disorder. Moreover, less than 6% of patients had a medical or 
surgical history of respiratory diseases, migraine, infectious diseases, or renal insufficiency.
Region Country Sites Participating physicians Screened patients Included patients*
Middle East
Israel 8 8 126 120
Iran 20 20 244 200
Africa
Tunisia 12 12 204 185
Egypt 20 20 301 300
South Asia Bangladesh 15 15 388 225
Eurasia Ukraine 15 14 184 150
Total 90 89 1447 1180
Table 1.  Recruitment plan. *All included patients were part of eligible population.
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Disease characteristics. Overall, 72.2% and 25.7% of patients were diagnosed with BD type I and type II, respec-
tively, (Table 2). The median time from initial diagnosis was 80 months (range: 0–608). Most patients (64.4%) 
were diagnosed before the age of 30. Major depressive disorder and BD were the predominant initial diagnoses 
(36.4% and 20.2%, respectively).
Most patients (80.8%) had experienced between one and three episodes in the last 12 months. The predomi-
nant polarity of episodes was manic (65.9%).
One third of patients had a first-degree relative suffering from BD.
Global assessment of functioning during the last two months revealed moderate social, familial, and occupa-
tional dysfunction with a mean GAF score of 54.7 ± 19.7.
Therapeutic management of BD. Therapies received at time of initial diagnosis. Overall, 67.2% of 
patients had received antipsychotic drugs at initial diagnosis, among them 51.1% received first-generation and 
51.6% second-generation (Table 3). Moreover, 44.4% of patients had received antidepressants at initial diagnosis, 
mainly selective serotonin reuptake inhibitors (SSRIs; 67.2%). Mood stabilizers and anxiolytics were prescribed 
at initial diagnosis to an equivalent number of patients (29.7% and 30.0%, respectively).
Among the 63.8% patients who had received antidepressant at least once in lifetime, 46.1% experienced manic 
or hypomanic switches, 30.3% experienced irritability, and 29.6% experienced mood lability.
Ongoing pharmacological treatment. At the time of the study 85.7% of patients were being treated with mood 
stabilizers, mostly anticonvulsants (84.3%), and 83.4% of patients were receiving antipsychotics with a predomi-
nance of second-generation antipsychotics (79.6%), (Table 3). Anxiolytics were the third most frequently received 
therapy in 51.4% of patients. Antidepressants were being administered to 36.1% of patients (mainly SSRIs).
N (%)
Bangladesh Egypt Iran Israel Tunisia Ukraine Total
225 (19.1) 300 (25.4) 200 (16.9) 120 (10.2) 185 (15.7) 150 (12.7) 1180 (100)
Patient’ characteristics
 Age (years), mean (SD) 31.6 (10.2) 34.4 (11.2) 38.0 (13.1) 47.8 (15.4) 41.5 (12.1) 42.0 (13.5) 37.9 (13.2)
 Male, n (%) 132 (58.7) 166 (55.3) 83 (41.5) 73 (60.8) 94 (50.8) 75 (50) 623 (52.8)
 Living in urban area, n (%) 110 (48.9) 179 (59.7) 171 (85.5) 96 (80.0) 139 (75.1) 123 (82.0) 818 (69.3)
 Married, n (%) 121 (53.8) 136 (45.3) 97 (48.5) 43 (35.8) 96 (51.9) 69 (46) 562 (47.6)
 Educational level, n (%)
Illiterate 16 (7.1) 29 (9.7) 6 (3.0) 2 (1.7) 8 (4.3) 0 (0.0) 61 (5.2)
Primary 71 (31.6) 34 (11.3) 30 (15.0) 9 (7.5) 31 (16.8) 2 (1.3) 177 (15.0)
Secondary 99 (44.0) 104 (34.7) 88 (44.0) 69 (57.5) 78 (42.2) 68 (45.3) 506 (42.9)
University 39 (17.3) 133 (44.3) 76 (38.0) 40 (33.3) 68 (36.8) 80 (53.3) 436 (36.9)
 Employed, n (%) 92 (40.9) 161 (53.7) 94 (47.0) 50 (41.7) 93 (50.3) 60 (40.0) 550 (46.6)
 Medication health coverage, n (%)
Total 9 (4.0) 29 (9.7) 39 (19.5) 111 (92.5) 109 (58.9) 10 (6.7) 307 (26.0)
Partial 28 (12.4) 24 (8.0) 146 (73.0) 0 (0.0) 39 (21.1) 12 (8.0) 249 (21.1)
None 188 (83.4) 247 (82.3) 15 (7.5) 9 (7.5) 37 (20.0) 128 (85.3) 624 (52.9)
 Co-morbidities, n (%)
Cardio-vascular 11 (4.9) 12 (4.0) 18 (9.0) 13 (10.8) 6 (3.2) 17 (11.3) 77 (6.5)
Obesity 28 (12.4) 30 (10.0) 32 (16.0) 14 (11.7) 8 (4.3) 7 (4.7) 119 (10.1)
Diabetes 14 (6.2) 12 (4.0) 13 (6.5) 9 (7.5) 2 (1.1) 1 (0.7) 51 (4.3)
Thyroid disorders 6 (2.7) 6 (2.0) 31 (15.5) 11 (9.2) 2 (1.1) 1 (0.7) 57 (4.8)
Disease characteristics
 Type BD I, n (%) 192 (85.3) 197 (65.7) 157 (78.5) 104 (86.7) 137 (74.1) 65 (43.3) 852 (72.2)
 Rapid cycler, n (%) 14 (6.2) 10 (3.3) 12 (6.0) 9 (7.5) 7 (3.8) 1 (0.7) 53 (4.5)
 Manic predominant polarity of episodes, n (%) 194 (86.2) 216 (72.0) 122 (61.0) 68 (56.7) 105 (56.8) 73 (48.7) 778 (65.9)
 Family history of BD among first degree relatives, n (%) 49 (21.8) 95 (31.7) 82 (41.0) 37 (30.8) 83 (44.9) 18 (12.0) 364 (30.8)
 Age (years) at initial diagnosis, mean (SD) 27.3 (8.2) 26.3 (9.3) 25.3 (9.9) 30.9 (13.7) 29.7 (11.2) 32.9 (10.4) 28.2 (10.5)
 Initial diagnosis type, n (%)
Major Depressive 61 (27.1) 99 (33.0) 83 (41.5) 44 (36.7) 74 (40.0) 69 (46.0) 430 (36.4)
Bipolar Disease 99 (44.0) 41 (13.7) 45 (22.5) 30 (25.0) 11 (5.9) 12 (8.0) 238 (20.2)
Brief Psychotic Disorder 35 (15.6) 62 (20.7) 27 (13.5) 13 (10.8) 38 (20.5) 13 (8.7) 188 (15.9)
Schizophrenia 11 (4.9) 22 (7.3) 9 (4.5) 7 (5.8) 18 (9.7) 8 (5.3) 75 (6.4)
Other 19 (8.4) 76 (25.3) 36 (18.0) 26 (21.7) 44 (23.8) 48 (32) 249 (21.1)
 Time (months) between initial and BD diagnosis, mean (SD) 17.8 (30.5) 32.6 (60.5) 50.6 (84.1) 73.7 (111.5) 57.4 (77.1) 49.7 (77.3) 43.1 (74.4)
 Functioning (GAF score) within the last 2 months, mean (SD) 45.9 (16.7) 57.1 (18.2) 53.3 (22.3) 50.1 (18.2) 64.0 (19.2) 57.1 (18.7) 54.7 (19.7)
Table 2.  Patient and disease characteristics by country. Abbreviations: BD – Bipolar Disorder; N – number 
of patients; SD – standard deviation.
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Psychiatric hospitalizations. 46.0% of patients had at least one psychiatric hospitalization in the last 12 months, 
(Table 3).
BD management according to type of BD and current symptomatology. BD type I versus BD type 
II. The average time from initial diagnosis to BD diagnosis was shorter for BD I patients (median, 0.8 years) 
than for BD II patients (median, 2.2 years), (Table 4). There was no observed difference in employment status 
and work disability based on the type of BD. However, BD I patients had a lower GAF score than BD II patients 
(53.8 ± 20.0 versus 56.9 ± 18.5, p = 0.017). BD I patients received more first-generation antipsychotics and anx-
iolytics than BD II patients (p < 0.001). Second-generation antipsychotics were used by more patients suffering 
from BD II than BD I (91.8% versus 75.9%). BD II patients received more antidepressants than BD I patients 
(p < 0.001). SSRIs remained the most common antidepressant for BD I (76.4%) and BD II (80.1%).
Current bipolar symptoms and treatment. Current symptoms of mania were associated with an increase in antip-
sychotic drug prescription (e.g., from 78.7% to 91.2% for “unrealistic or grandiose beliefs about one’s abilities 
or powers” (p < 0.001)). Patients who reported “racing thoughts: jumping quickly from one idea to the next” 
or “sleeping very little, but feeling extremely energetic,” used more mood stabilizers than others (90.0% versus 
83.2%, p = 0.001 and 88.6% versus 82.6%, p = 0.003, respectively). Mania was also associated with decrease in 
antidepressant drug prescription.
Existing symptoms of bipolar depression were associated with a decrease in antipsychotic drug prescription 
(except for “feelings of worthlessness or guilt”, “thoughts of death or suicide”, and “irritability” (p < 0.01)) and an 
increase in antidepressant drug prescription (e.g., from 21.5% to 73.3% for “hopelessness, sadness or emptiness 
feelings” (p < 0.001)).
Most of these results (except decrease of antipsychotic prescription according to the presence of depressive 
symptoms) remained significant after Bonferroni correction (p < 0.0025).
Treatment received at the time of initial diagnosis
 Antidepressants, n (%) 524 (44.4)
 Antipsychotics, n (%) 793 (67.2)
 Mood stabilizers, n (%) 350 (29.7)
 Anxiolytics, n (%) 354 (30.0)
Previous response to antidepressant
 Antidepressant received at least once lifetime, n (%) 753 (63.8)
Manic/hypomanic switches 347 (46.1)
Irritability 228 (30.3)
Mood lability 223 (29.6)
Resistance to treatment 148 (19.7)
Unknown 122 (16.2)
Ongoing pharmacological treatment
 Antidepressants, n (%) 426 (36.1)
SSRIs 333 (78.2)
SNRIs 92 (21.6)
TCAs 98 (23.0)
 Antipsychotics, n (%) 984 (83.4)
FGA 403 (41.0)
SGA 783 (79.6)
 Mood stabilizers, n (%) 1011 (85.7)
Lithium 395 (39.1)
Anticonvulsants 852 (84.3)
 Electroconvulsive therapy, n (%) 187 (15.8)
 Anxiolytics, n (%) 606 (51.4)
Benzodiazepines 588 (97.0)
Other 43 (7.1)
Psychiatric hospitalizations in last 12 months
 One, n (%) 408 (34.6)
 Multiple, n (%) 135 (11.4)
Table 3.  Main outcomes evaluating the management of BD. Abbreviations: BD – bipolar disorder; FGA – 
first-generation antipsychotic; SGA – second-generation antipsychotic; SNRI – serotonin and norepinephrine 
reuptake inhibitors; SSRI – selective serotonin reuptake inhibitors; TCA – tricyclic antidepressants.
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Discussion
This is the primary report from the MAPING study, which was designed to describe the clinical management of 
BD under real-life conditions across 6 countries (Bangladesh, Egypt, Iran, Israel, Tunisia, and Ukraine) from the 
intercontinental region.
Our findings show that, in the countries included:
•	 There is frequent initial misdiagnosis as major depressive disorder with resultant delay in the diagnosis of BD;
•	 Preferential use of anticonvulsants and second-generation antipsychotics in the treatment of BD with an 
overuse of antidepressants;
•	 Decision-making about treatment is based on BD type and existing symptoms.
In spite of some cultural aspects such as difference in medication health coverage, this is greatly similar to the 
clinical management of patients with BD in western countries24–33.
The challenges in diagnosing BD at the onset of disease arise from its complex and heterogeneous clinical 
presentation. As the first mood episode is frequently a depressive phase for BD patients, major depressive dis-
order was the predominant initial diagnosis in our study. The lifetime prevalence of major depressive disorder 
is approximately 4 times that of BD spectrum disorders, and the clinical presentation of a bipolar depression 
episode does not differ significantly from unipolar depression36. Consequently, there is often a delay of several 
years between initial diagnosis and BD diagnosis, associated with an initial over-prescription of antidepressants in 
44.4% of patients. This issue is even more problematic in BD II patients, who are less quickly identified and con-
sequently receive more antidepressants than BD I patients. The challenges of accurately identifying BD patients 
in clinical practice are similarly reported in western countries36–38. Therefore, the systematic screening of depres-
sive patients with accurate assessment scales to identify hypomanic episodes, and the consideration of clinical 
characteristics associated with bipolar depression (family history of BD, earlier onset of illness, seasonality, mood 
reactivity, switching on antidepressants, history of suicide attempt) needed to be implemented in routine practice 
in all countries over the world13,36,39,40. In the future, an integrative approach with combinations of objective bio-
markers could help in the differentiation between BD and unipolar depression41.
Overall, the most commonly prescribed medications were anticonvulsants, second-generation antipsychotics, 
and anxiolytics (almost always benzodiazepines). Over one third of patients were treated with antidepressants 
in spite of the increased risks of manic switches, irritability, mood lability, or inadequate response to treatment. 
Previous studies in western countries found the same trends of prescription in the treatment of BD. Psychotropic 
medications mainly involved antidepressants, anticonvulsants and second-generation antipsychotics in the 
United States28,30 and the European countries25.
Although most participating psychiatrists regularly used international guidelines to facilitate decision-making 
about treatment for BD management, they reported a preference for certain drugs depending on the type of BD or 
current bipolar symptoms. The presence of manic symptoms was associated with an increased use of antipsychot-
ics and a decreased use of antidepressants. Conversely, depressive symptoms were associated with an increased 
use of antidepressants and a decreased use of antipsychotics. BD I patients received more first-generation 
BD type I N = 852 BD type II N = 303 Total N = 1155 p-value
Time between initial and BD diagnosis 
(months), mean (SD) [median] 37.3 (68.4) [9.0] 59.5 (87.2) [26.1] 43.1 (74.4) [12.0] < 0.001
*
Occupational status and productivity
 Employed, n (%) 387 (45.4) 151 (49.8) 538 (46.7) 0.095**
 Work disability#, n (%) 222 (47.7) 71 (46.7) 293 (47.5) 0.825**
GAF score in the last 2 months, mean (SD) 53.8 (20.0) 56.9 (18.5) 54.6 (19.6) 0.017*
Associated therapy received
Antidepressants, n (%) 237 (27.8) 176 (58.1) 413 (35.8) < 0.001**
 SSRIs 181 (76.4) 141 (80.1) 322 (78.0) 0.364**
 SNRIs 43 (18.1) 45 (25.6) 88 (21.3) 0.068**
 TCAs 58 (24.5) 39 (22.2) 97 (23.5) 0.583**
Antipsychotics, n (%) 747 (87.7) 219 (72.3) 966 (83.6) < 0.001**
 FGA 349 (46.7) 48 (21.9) 397 (41.1) < 0.001**
 SGA 567 (75.9) 201 (91.8) 768 (79.5) < 0.001**
Mood stabilisers, n (%) 733 (86.0) 261 (81.6) 994 (86.1) 0.964**
 Lithium 295 (40.2) 93 (35.6) 388 (39.0) 0.189**
 Anticonvulsants 622 (84.9) 213 (81.6) 835 (84.0) 0.219**
Electroconvulsive therapy, n (%) 138 (16.2) 46 (15.2) 184 (15.9) 0.678**
Anxiolytics, n (%) 467 (54.8) 125 (41.3) 592 (51.3) < 0.001**
Table 4.  Bipolar disorder type I and II comparisons. Abbreviations: BD – Bipolar disorder; FGA – first-
generation antipsychotic; GAF – Global Assessment of Functioning scale; N – number of patients; SD – 
Standard Deviation; SGA – second-generation antipsychotic; SNRI – serotonin and norepinephrine reuptake 
inhibitors; SSRI – selective serotonin reuptake inhibitors; TCA – tricyclic antidepressants. *p-value, Wilcoxon-
Mann-Whitney test (Two-sided). **p-value, Chi-square test. #Only for the unemployed patients.
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antipsychotics and anxiolytics and BD II patients received more SSRIs, antidepressants, and second-generation 
antipsychotics. These findings are again in accordance with western studies. Several observational studies found 
highest antidepressant use in depression and higher second-generation antipsychotic prescription in mania25,30,32. 
In European countries, the BD II patients received more antidepressants33 and the BD I patients were treated with 
more antipsychotics in monotherapy or combination29.
Although most guidelines have focused on the use of mood stabilizers and not antidepressants, which are 
never recommended as monotherapy for acute or maintenance BD therapy, the use of antidepressants for the 
treatment of BD patients is still controversial42. As per certain international guidelines, insufficient levels of evi-
dence justify that SSRIs in combination with mood stabilizers should not be recommended in bipolar depression, 
whereas other guidelines are more flexible regarding the use of antidepressants, particularly for BD II patients43. 
Inconclusive evidence is also available to consider antidepressant in combination with a prophylactic agent in 
the prevention of depressive episode42. All guidelines recommend avoiding antidepressant in patients with rapid 
cycling or history of mood switch during their use. If recent studies showed the possible interest of modern antide-
pressants in BD type II patients with lower risk of switching than BD type I, larger prospective trials are needed to 
confirm these findings44,45. The lack of expert consensus, paucity of evidence, and variability in guideline quality46  
may explain the frequent use of antidepressants in our study but also in western countries.
Another relevant finding is the low rate of lithium use in comparison with anticonvulsants and 
second-generation antipsychotics, despite the fact that all international guidelines consider lithium as a first-line 
treatment in the acute manic phase and for prophylaxis47. As described in previous western studies19,25–27,30, the 
use of lithium seems to be declining due to clinicians’ apprehensions regarding the risk of side effects or intoxica-
tion, the long onset of action, or the practicability. The decline may also be the result of the recent development 
of second-generation antipsychotics for treatment of BD, and the lack of promotion of lithium, which is a generic 
and old medication.
Despite the large sample size, this study has several limitations. The cross-sectional design does not allow 
analysis of the causal relationship between the outcomes associated with management of bipolar patients and 
the different variables tested. The study did not involve all countries from the Middle East, Africa, South Asia, 
or Eurasia but selected some countries from these regions. The results cannot be considered as representative of 
routine clinical practice of regions that were not included in this study. Therefore, the analyses performed did not 
directly compare these intercontinental regions to each other. The high rates of type I BD and manic predominant 
polarity in this study, even if their prevalence varied broadly across studies, represent another limitation, which 
may be related to a selection bias.
Finally, the assessment of BD management was limited to patients who had access to the mental health care 
system, and BD patients without access to such care were not assessed.
In conclusion, the MAPING study provides relevant information on the management of BD patients in condi-
tions representative of everyday clinical practice across 6 countries from the intercontinental region. An analysis 
of the findings indicates broad similarities in clinical management of BD patients included and those more widely 
studied in western countries. The real-life management of BD, irrespective of the country or region, shows a delay 
in diagnosis and is associated with a substantial use of antipsychotics, anticonvulsants, and SSRIs. Moreover, 
clinicians appear to base their decision making on a multidimensional approach related to the presence of manic 
or depressive symptoms. Taken together, management of patients with BD II presented some specific differences 
compared to management of those with BD I.
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